title: Effect of subcutaneous depot-medroxyprogesterone acetate (DMPA-SC) on serum androgen markers in normal-weight, obese, and extremely obese women.
abstract: BACKGROUND
  The effects of subcutaneous depo-medroxyprogesterone acetate (DMPA-SC) injection on androgenic markers in obese women have not previously been studied.
  
  
  METHODS
  Five normal-weight [body mass index (BMI)=18.5-24.9 kg/m²], five obese (BMI=30-39.9 kg/m²) and five extremely obese (BMI≥40 kg/m²) women were recruited for this prospective experimental study in which 104 mg DMPA-SC was administered at baseline and 12 weeks later. Serum levels of total testosterone (T), androstenedione (A), dehydroepiandrosterone sulfate (DHEAS), 3α-androstanediol glucuronide and sex hormone-binding globulin (SHBG) were quantified by immunoassay methods at baseline and at 13 and 26 weeks following the first injection; free T was calculated.
  
  
  RESULTS
  At baseline, obese women had lower levels of A and SHBG and higher total and free T levels than normal-weight women. There were a statistically significant decrease in the levels from baseline to week 26 among all three BMI classes for A, total T and SHBG (p≤.03) and an increase from baseline to week 26 in weight (p=.02). In addition, there was a statistically significant decrease in DHEAS from baseline to week 13 among all three BMI classes (p=.01), which was not sustained at week 26 (p>.1). Overall, the three groups responded similarly to all changes at week 13, and there were no statistically significant differences between groups at any time point (p≥.06).
  
  
  CONCLUSIONS
  DMPA-SC use in normal-weight, obese and extremely obese women can decrease serum androgen markers.
authors.affiliation: Department of Obstetrics and Gynecology, Los Angeles, CA 90033, USA. psegall@usc.edu
authors.forename: Penina
authors.initials: P
authors.lastname: Segall-Gutierrez
authors.forename: Joanna
authors.initials: J
authors.lastname: Du
authors.forename: Chunying
authors.initials: C
authors.lastname: Niu
authors.forename: Marshall
authors.initials: M
authors.lastname: Ge
authors.forename: Ian
authors.initials: I
authors.lastname: Tilley
authors.forename: Kelly
authors.initials: K
authors.lastname: Mizraji
authors.forename: Frank Z
authors.initials: FZ
authors.lastname: Stanczyk
mesh_terms: D000328:Adult; D000726:Androgen Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D000728:Androgens / Q000097:blood*; D015113:Androstane-3,17-diol / Q000031:analogs & derivatives / Q000097:blood; D000735:Androstenedione / Q000097:blood; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D003271:Contraceptive Agents, Female / Q000008:administration & dosage / Q000009:adverse effects*; D019314:Dehydroepiandrosterone Sulfate / Q000097:blood; D004343:Drug Implants; D005260:Female; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000009:adverse effects*; D009765:Obesity / Q000097:blood / Q000378:metabolism*; D009767:Obesity, Morbid / Q000097:blood / Q000378:metabolism*; D012738:Sex Hormone-Binding Globulin / Q000032:analysis; D040521:Subcutaneous Tissue; D013739:Testosterone / Q000097:blood; D013997:Time Factors; D055815:Young Adult
chemical_list: D000726:Androgen Antagonists; D000728:Androgens; D015415:Biomarkers; D003271:Contraceptive Agents, Female; D004343:Drug Implants; D012738:Sex Hormone-Binding Globulin; D015113:Androstane-3,17-diol; C028895:androstane-3,17-diol glucuronide; D013739:Testosterone; D000735:Androstenedione; D019314:Dehydroepiandrosterone Sulfate; D017258:Medroxyprogesterone Acetate